Effect of naltrexone in chronic urticaria

Effect of naltrexone in treatment of chronic urticaria: double-blinded randomized clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210407050878N1

Enrollment

Registered

2021-06-29

Start date

2021-07-21

Completion date

Unknown

Last updated

2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urticaria. Urticaria

Interventions

Intervention 1: Intervention group: Tab Cetrizine 10mg,One every 6 hours (manufactured by Abidi Co., Iran)

Tab Famotidin 40 mg, One every 12 hours ( manufactured by Shafa Darou Co.Iran) and Tab Montellukast 10 mg, once daily (manufactured by Zahravi Co.Iran) as the main treatment that start from one week b

Eligibility

Sex/Gender

All

Age

12 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of chronic urticaria based on clinical criteria Lack of response to standard treatment Patients of both males and females Age over 12 years

Exclusion criteria

Exclusion criteria: Pregnancy Breast feeding Allergy to naltrexone Substance abuse

Design outcomes

Primary

Measure	Time frame
Itching Score based on UAS7 (Urticaria Activity Score7). Timepoint: Itching score based on UAS7 (Urticaria Activity Score7): During the week before beginning intervention, during the second week of intervention, during the fourth week of intervention. Method of measurement: Based on UAS7 (Urticaria Activity Score7).;Urticaria Score based on UAS7 (Urticaria Activity Score7). Timepoint: Urticaria score based on UAS7 (Urticaria Activity Score7): during the week before beginning intervention, during the second week of intervention, during the fourth week of intervention. Method of measurement: Based on UAS7 (Urticaria Activity Score7).	—

Measure

Time frame

Itching Score based on UAS7 (Urticaria Activity Score7). Timepoint: Itching score based on UAS7 (Urticaria Activity Score7): During the week before beginning intervention, during the second week of intervention, during the fourth week of intervention. Method of measurement: Based on UAS7 (Urticaria Activity Score7).;Urticaria Score based on UAS7 (Urticaria Activity Score7). Timepoint: Urticaria score based on UAS7 (Urticaria Activity Score7): during the week before beginning intervention, during the second week of intervention, during the fourth week of intervention. Method of measurement: Based on UAS7 (Urticaria Activity Score7).

—

Secondary

Measure	Time frame
Itching score based on VAS (Visual Analogue Scale). Timepoint: Before intervention, end of the second week of intervention, end of the fourth week of intervention. Method of measurement: Based on VAS (Visual Analogue Scale).;Quality of life based on DLQI (Dermatologic Life Quality Index). Timepoint: Before intervention, end of the second week of intervention, end of the fourth week of intervention. Method of measurement: Based on DLQI (Dermatologic Life Quality Index).	—

Measure

Time frame

Itching score based on VAS (Visual Analogue Scale). Timepoint: Before intervention, end of the second week of intervention, end of the fourth week of intervention. Method of measurement: Based on VAS (Visual Analogue Scale).;Quality of life based on DLQI (Dermatologic Life Quality Index). Timepoint: Before intervention, end of the second week of intervention, end of the fourth week of intervention. Method of measurement: Based on DLQI (Dermatologic Life Quality Index).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVahid Bakrani Balani

Iran University of Medical Sciences

bakranibalani.v@iums.ac.ir+98 21 6655 4933

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026